This report provides a detailed cost and benefit analysis for implementing neuromuscular monitoring in your facility using the STIMPOD device. It covers key parameters influencing the overall cost structure, including drug savings, implementation costs, and reductions in post-operative complications. The analysis is designed to help hospitals and healthcare providers make informed decisions about the cost-efficiency of STIMPOD.
The STIMPOD is a state-of-the-art neuromuscular transmission (NMT) monitor that offers dual AMG (Acceleromyography) and EMG (Electromyography) technology. With STIMPOD, clinicians have the advantage of both technologies to ensure precise and reliable monitoring, significantly reducing the risk of residual neuromuscular blockade (NMB). Its superior accuracy and ease of use make it the preferred choice for eliminating post-operative complications associated with neuromuscular blockade, ensuring better patient outcomes.
The basic parameters selected in this analysis, including currency, the number of operating theatres, and the annual procedure volume per theatre, serve as foundational inputs for the cost and benefit calculations. These parameters define the scope of the analysis and directly impact the overall cost of implementation and projected savings. By customizing these values to reflect real-world conditions, this report provides a tailored view of the financial impact of implementing NMT monitoring with the STIMPOD system.
The currency selection dictates the financial calculations and display format, while the number of theatres and procedure volume are used to calculate both the upfront and ongoing costs of implementation, including equipment and disposables usage. These figures are critical in determining cost-effectiveness and ensuring the analysis is relevant to the healthcare facility’s operational capacity.
The STIMPOD provides a cost-effective solution with lower installation and consumable costs compared to alternative products, offering long-term savings through the use of its AMG and EMG technology in a single device. Figures are cummulative over 5 years.
| Year | STIMPOD Lifecycle Cost | Product B Lifecycle Cost | Cost Savings |
|---|
The STIMPOD's precise monitoring reduces drug usage, leading to significant savings on muscle relaxants and reversal agents. This section explores the potential savings on reversal agents. Figures are cummulative over 5 years. [Ref1]
| Year | Pre-Implementation Cost | Post-Implementation Cost | Cost Savings |
|---|
The STIMPOD helps decrease post-operative complications, particularly respiratory issues, resulting in improved patient safety and significant cost savings. This section explores the extent of these potential cost savings. Figures are cummulative over 5 years. [Ref1,2]
| Year | Pre-Implementation Cost | Post-Implementation Cost | Cost Savings |
|---|
The STIMPOD delivers substantial cumulative cost savings with lower drug costs, fewer complications, and efficient implementation. The analysis below reflects the time taken for drug savings to cover the implementation cost, highlighting when the hospital reaches a net positive benefit.
| Year | Lifecycle Cost | Reduced Drugs Benefit | Reduced POPC Benefit | Net Benefit |
|---|
1. Quantitative Neuromuscular Monitoring in Clinical Practice: A Professional Practice Change Initiative
2. Universal quantitative neuromuscular blockade monitoring at an academic medical center — A multimodal analysis of the potential impact on clinical outcomes and total cost of care
The information provided in this report is for informational purposes only and is based on clinical data, financial estimates, and market research. Individual results and cost savings may vary depending on specific clinical practices and institutional settings. Xavant Technology assumes no liability for the accuracy of the projected savings or clinical outcomes presented in this report.
© 2024 Xavant Technology (Pty) Ltd. All rights reserved. This report and its contents are the intellectual property of Xavant Technology. It may be freely distributed in its original form without alteration. Reproduction, modification, or transmission of this report in any other form is prohibited without prior written permission.